MDGL— MADRIGAL PHARMACEUTICALS, INC.

MaterialsBiotechnology$11.9B mkt cap

Metric	FY2025	FY2024	FY2023	FY2023
Product revenue, net	$958.4M+432.1%	$180.1M	$0	—
Cost of sales	$56.1M+800.8%	$6.2M	$0	—
Research and development	$388.5M+64.1%	$236.7M-13.1%	$272.4M+283.9%	$71.0M
Selling, general and administrative	$813.8M+87.1%	$435.1M+302.3%	$108.1M	—
Total operating expenses	$1.26B+85.6%	$678.0M+78.2%	$380.5M+286.2%	$98.5M
Loss from operations	-$300.1M+39.7%	-$497.9M-30.8%	-$380.5M-286.2%	-$98.5M
Interest income	$37.4M-19.9%	$46.7M+138.3%	$19.6M+493.6%	$3.3M
Interest expense	-$22.3M-52.1%	-$14.7M-15.4%	-$12.7M-262.8%	-$3.5M
Loss on extinguishment of debt	-$2.8M	$0	$0	—
Other expense, net	-$463K	$0	$0	—
Net loss	-$288.3M+38.1%	-$465.9M-24.7%	-$373.6M-278.4%	-$98.7M
Basic net loss per common share (in dollars per share)	-$12850.00+41.3%	-$21900.00-9.6%	-$19990.00-374244.6%	-$5.34
Diluted net loss per common share (in dollars per share)	-$12850.00+41.3%	-$21900.00-9.6%	-$19990.00-374244.6%	-$5.34
Basic weighted average number of common shares outstanding (in shares)	22.43B+5.5%	21.27B+13.8%	18.69B+101043.9%	18.5M
Diluted weighted average number of common shares outstanding (in shares)	22.43B+5.5%	21.27B+13.8%	18.69B+101043.9%	18.5M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.